An Open, Dose-escalation, Phase 1b Clinical Trial to Evaluate the Safety and Efficacy of EN001 in Patients With Charcot-Marie-Tooth Disease Type 1A (CMT1A)
Latest Information Update: 29 Aug 2025
At a glance
- Drugs EN 001 (Primary)
- Indications Charcot-Marie-Tooth disease
- Focus Adverse reactions
- Sponsors ENCell
Most Recent Events
- 12 Aug 2025 Planned End Date changed from 1 Oct 2024 to 1 Oct 2025.
- 12 Aug 2025 Planned primary completion date changed from 1 Oct 2024 to 1 Oct 2025.
- 12 Aug 2025 Status changed from recruiting to active, no longer recruiting.